Many large clinical studies have shown that in advanced NSCLC with EGFR mutant, especially NSCLC patients with 19 Exon deletion or 21 Exon L858R mutant, the progression-free survival (PFS) and overall survival (OS) of the first-generation EGFR-TKIs as the first-line treatment plan are significantly longer than those of the traditional first-line chemotherapy plan based on platinum (carboplatin, cisplatin, Nedaplatin, etc.). Here, EGFR is linked to non-small cell lung carcinoma.